Welcome to our dedicated page for Victory Square news (Ticker: VSQTF), a resource for investors and traders seeking the latest updates and insights on Victory Square stock.
Victory Square Technologies Inc. reports portfolio and capital-allocation developments for a venture builder focused on healthcare infrastructure, digital health, artificial intelligence and emerging technology platforms. Recurring updates cover operating and financial results, platform scaling, normal course issuer bid activity and the progress of portfolio companies.
Company news frequently centers on Hydreight and VSDHOne, including compliant patient access, prescribing, pharmacy fulfillment and healthcare delivery across categories such as GLP-1 therapies, peptides, hormone optimization, diagnostics and wellness programs. Other portfolio themes include Insu Therapeutics' peptide delivery work and Pawsible Ventures' activity in pet wellness, AI and health technology.
Victory Square (OTCQX: VSQTF) updated shareholders on its healthcare portfolio following Hydreight Technologies’ July 29, 2026 disclosure about FDA Pharmacy Compounding Advisory Committee recommendations on certain peptide-related bulk drug substances. The committee advised adding six peptides, including BPC-157 and TB-500, to the Section 503A Bulks List, but not Emideltide (DSIP); these recommendations are non-binding and are not FDA approvals.
Victory Square holds about 44.5% of Hydreight, whose U.S. digital healthcare platform spans all 50 states with more than 12,000 VSDHOne licenses sold, 300+ physicians, 3,000+ nurses and over 45 physician-supervised treatments, including peptide-based and GLP-1 therapies. The company also highlighted Insu Therapeutics’ buccal peptide/biologic delivery platform under development and its Pawsible companion animal health initiative, and reminded investors of an Insu-focused shareholder webinar on August 5, 2026.
Hydreight Technologies (OTCQB: HYDTF) provided a business update on its peptide healthcare platform following the July 23–24, 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC). The committee recommended six peptide-related bulk drug substances (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) for potential inclusion on the Section 503A Bulks List, a step that is advisory only and does not constitute FDA approval.
According to Hydreight, peptide-based therapies are already a significant part of its physician-supervised, nationwide platform, which supports GLP-1 therapies, Sermorelin, Ipamorelin and other personalized treatments. The company reports more than 12,000 VSDHOne licenses sold (vs. approximately 3,000 at the end of 2025), a network of 300+ licensed physicians, over 3,000 licensed nurses, a pharmacy network covering all 50 U.S. states and more than 45 physician-supervised treatment offerings. Hydreight also highlights prior investments in clinical protocols, pharmacy relationships, proprietary technology and a strategic investment in Insu Therapeutics, stating these were driven by its long-term personalized medicine strategy rather than the recent PCAC recommendations.
Victory Square (OTCQX:VSQTF) reported strong Q1 2026 results, with revenue up to $24.9 million from $4.5 million in Q1 2025 and net income of $3.9 million. Cash and marketable securities reached about $31 million, enhancing liquidity.
Results were mainly driven by Hydreight Technologies, which grew its VSDHOne platform to over 12,000 licenses, completed a $15 million financing, and launched an NCIB. Insu completed Phase I preclinical studies for buccal semaglutide and secured approval to start Phase II. Pawsible Ventures launched a pet-health platform, $10 million fund, and its inaugural cohort.
Hydreight (VSQTF) reported record Q1 2026 revenue of $24.9M, up 449% year-over-year, and non-GAAP Adjusted Revenue of $27.6M. Adjusted EBITDA reached about $3.3M with a 13.1% margin, and net income was $2.6M.
Hydreight ended the quarter with $24.2M in cash, $32.0M in working capital, and $36.4M in shareholders' equity. The platform now spans all 50 U.S. states with over 12,000 VSDHOne licenses sold and expanding pharmacy and strategic healthcare partnerships.
Hydreight Technologies (OTCQB: HYDTF) will release its Q1 2026 financial results after market close on Monday, June 1, 2026. Management will host an investor webcast and conference call on Tuesday, June 2, 2026 at 6:00 a.m. PT / 9:00 a.m. ET.
The webcast, led by CEO Shane Madden, will cover Q1 2026 results, business operations, VSDHOne platform growth, onboarding momentum, operating leverage, new healthcare verticals, pharmacy financing initiatives, and the company’s 2026 growth strategy and outlook. A replay will be available.
Victory Square (OTC: VSQTF) reported audited fiscal 2025 results on May 1, 2026, showing consolidated revenue of $35.4M and adjusted revenue of $43.56M. Hydreight, 51.03% owned, drove results with revenue up 121% YoY, adjusted EBITDA of $2.5M, and year-end cash of $15.65M.
The company highlighted improved operating leverage (OPEX/revenue ~22%), >11,000 VSDHOne licenses, national U.S. platform coverage, and a portfolio focus on healthcare infrastructure, AI, and emerging technologies.
Hydreight (OTCQB:VSQTF) reported audited 2025 results: GAAP revenue $35.4M, Adjusted Revenue $43.56M, net income $1.69M and Adjusted EBITDA $2.54M. Cash improved to $15.65M at year-end and the company completed a $15M financing in January 2026. Platform scale: >11,000 VSDHOne licenses (Q1 2026: >12,000). Q4 revenue was $14.95M, reflecting accelerating adoption and improved operating leverage.
Hydreight (OTCQB: HYDTF; TSXV: NURS) announced a normal course issuer bid to repurchase up to 4,951,189 common shares, representing ~9.27% of issued shares and ~10.0% of the public float. The Bid runs from March 12, 2026 to March 11, 2027.
Purchases will be made on the Exchange at prevailing market prices through Research Capital Corporation and funded from existing working capital. The company said purchases aim to facilitate an orderly market and could be used if shares trade below perceived underlying value.
Victory Square (OTC: VSQTF) provided a 2026 corporate update focusing on scaling healthcare infrastructure across digital health, biotech, pet health, diagnostics and immersive tech.
Key points: Hydreight guidance of ~$150M FY2026 and Q1 revenue of $25–28M, a $10M Digital Health Accelerator, Pawsible's $10M pet health fund and SafeTest diagnostics progress in Brazil. XR is working to lift a Cease Trade Order while pursuing debt restructuring.
Victory Square Technologies (OTC: VSQTF) reported Q3 2025 results and a corporate update across digital health, biotech, pet wellness, climate tech, and immersive tech.
Q3 highlights: Adjusted revenue $12.83M, GAAP revenue $10.52M, gross margin $2.33M, adjusted EBITDA $1.26M, and cash & marketable securities $25.91M. Nine-month adjusted revenue was $26.71M (GAAP $20.44M).
Portfolio notes: Hydreight showed >100% YoY revenue growth, four consecutive profitable quarters and $18.64M cash; Insu targets first-in-human studies in 2026; Pawsible launched a $10M fund; NCIB authorizes repurchase of up to 5,000,000 shares.